|
| 阅读上一个主题 :: 阅读下一个主题 |
| 作者 |
 中国应迅速引进转基因老鼠以制造SARS特异性抗体, |
 |
| 所跟贴 |
转基因老鼠与制造SARS特异性抗体有何相关?只有转humanized Ig mouse也许有点用 -- Anonymous - (0 Byte) 2003-5-01 周四, 上午8:40 (111 reads) |
非文人
[个人文集]
加入时间: 2004/02/14
文章: 3936
经验值: 17496
|
|
|
作者：非文人 在 罕见奇谈 发贴, 来自 http://www.hjclub.org
About twenty-five years ago, scientists recognized that if antibodies could
be created in the laboratory, they could potentially function as a powerful
tool for the treatment of many diseases. These efforts were partially successful
when scientists discovered a way to make monoclonal antibodies using laboratory
mice. Mouse-generated monoclonal antibodies, however, were often rejected
by patients whose immune systems recognized them as foreign because they
were not human proteins, and the patients produced a human anti-mouse antibody,
or HAMA, response. This response reduces the effectiveness of the antibody
by neutralizing the binding activity and by rapidly clearing the antibody
from circulation in the body. The HAMA response can also cause significant
toxicities with subsequent administrations of mouse antibodies.
Subsequent generations of antibodies have been re-engineered to address
these immunogenic complications, resulting in monoclonal antibodies that
are less mouse and more human. Scientists developed "chimeric antibodies,"
which still contain mouse protein sequences (approximately 33%) but also
contain human protein sequences (approximately 66%). Although chimeric antibodies
are "more human" and theoretically, less likely to trigger an immune reaction,
they nonetheless can trigger a human anti-chimera antibody response by the
human immune system. Scientists then developed CDR-grafted or "humanized"
antibodies which contain approximately 5% to 10% mouse protein sequences.
Through our UltiMAb Human Antibody Development System, we can create all
types of antibodies that are fully human (100% human protein sequences)
by using transgenic mice in which mouse antibody gene expression is suppressed
and effectively replaced with human antibody gene expression. Because our
mice contain genes encoding human antibodies, we believe the monoclonal
antibodies we generate are more likely to have favorable safety profiles
and be eliminated less rapidly from the human body, potentially reducing
the frequency and amount of dosing required to affect disease targets. Additionally,
our fully human monoclonal antibodies do not require any humanization,
a process that at times has proven to be challenging and time consuming,
and can result in antibodies with lowered affinities for their respective
targets.
作者：非文人 在 罕见奇谈 发贴, 来自 http://www.hjclub.org |
|
|
| 返回顶端 |
|
 |
| |
|
|
您不能在本论坛发表新主题
您不能在本论坛回复主题
您不能在本论坛编辑自己的文章
您不能在本论坛删除自己的文章
您不能在本论坛发表投票
您不能在这个论坛添加附件
您不能在这个论坛下载文件
|
based on phpbb, All rights reserved.
|
